| Expression pattern: |
UP |
| Associated gene: |
FPR2, MAPK pathway |
| Associated microRNA: |
miR-375 |
| Biological function: |
Circ-ADAM9 promotes insulin resistance, dysregulated lipid metabolism, placental apoptosis, oxidative stress, pancreatic lesions, and adverse fetal outcomes in GDM; circ-ADAM9 knockdown restores trophoblast cell viability and reduces HG-induced apoptosis and ROS production. |
| Molecular mechanism: |
circ-ADAM9 acts as a ceRNA that sponges miR-375, thereby upregulating FPR2 expression and activating the MAPK pathway in GDM-related placental injury and trophoblast dysfunction. |
| Biological pathway or process: |
MAPK (promotes); apoptosis (promotes); lipid metabolism (other); ceRNA regulation (promotes); other pathway/process (promotes) |
| Detected method: |
Q
M
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; RT-qPCR; Microarray; Clinical Sample Validation; Luciferase Reporter Assay; RNA Pull-Down; RIP (RNA Immunoprecipitation); Transfection; CCK8; Annexin V/PI Flow Cytometry; TUNEL; In Vivo Animal Model; H&E Staining; ELISA; Western Blot; Bioinformatics Analysis |
| Clinical significance: |
circ-ADAM9 may offer a novel therapeutic target for the treatment of GDM. |
| Description: |
circ-ADAM9 is up-regulated in GDM patient blood, GDM mice, and HG-induced trophoblast cells. Its knockdown alleviates insulin resistance, lipid metabolic abnormalities, placental apoptosis, oxidative stress, and fetal impairment. Mechanistically, circ-ADAM9 sponges miR-375 to increase FPR2 expression and activate MAPK signaling, making it a potential therapeutic target for GDM. |
| Confidence score: |
0.8279 |